Acorda Stock Soars on European Surprise

12:42 EDT 20 May 2011 |

The European Medicine Agency (EMA) recommended conditional marketing authorization of Acorda Therapeutics’ (NASDAQ: ACOR) prolonged-release multiple sclerosis drug, fampridine (Fampyra), for the improvement of walking in adult patients, according to a press release. Surprised investors pushed Acorda’s stock up 13% in morning trading to $30.22. The reversal of opinion was unexpected because even though the drug was [...]

Original Article: Acorda Stock Soars on European Surprise


More From BioPortfolio on "Acorda Stock Soars on European Surprise"

Quick Search


Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...